Analysen von Mark Purcell
| 06.01.23 | Novartis Underweight | Morgan Stanley | |
| 09.11.20 | Novo Nordisk Underweight | Morgan Stanley | |
| 01.09.20 | GSK verkaufen | Morgan Stanley | |
| 03.03.20 | GSK Underweight | Morgan Stanley | |
| 06.01.20 | GSK verkaufen | Morgan Stanley | |
| 06.01.20 | Novartis verkaufen | Morgan Stanley | |
| 22.10.19 | Novartis Underweight | Morgan Stanley | |
| 21.10.19 | Novartis Underweight | Morgan Stanley | |
|
Werbung
|
|||
| 17.06.19 | GSK Underweight | Morgan Stanley | |
| 30.05.19 | Novartis Underweight | Morgan Stanley | |
| 10.04.19 | Novartis Underweight | Morgan Stanley | |
| 14.12.18 | GSK Underweight | Morgan Stanley | |
| 29.07.15 | Bayer Underweight | Barclays Capital | |
| 01.04.15 | AstraZeneca Underweight | Barclays Capital | |
| 01.04.15 | Bayer Underweight | Barclays Capital | |
| 16.01.15 | AstraZeneca Underweight | Barclays Capital | |
| 16.01.15 | Bayer Underweight | Barclays Capital | |
| 16.10.14 | STADA Underweight | Barclays Capital | |
| 16.10.14 | Merck Underweight | Barclays Capital | |
| 14.07.14 | STADA Underweight | Barclays Capital | |
| 14.07.14 | Merck Underweight | Barclays Capital | |
| 23.04.14 | Novartis Underweight | Barclays Capital | |
| 14.04.14 | STADA Underweight | Barclays Capital | |
| 14.04.14 | Merck Underweight | Barclays Capital | |
| 10.03.14 | STADA Underweight | Barclays Capital | |
| 10.03.14 | Novartis Underweight | Barclays Capital | |
| 10.03.14 | Merck Underweight | Barclays Capital | |